Structure-activity analysis of peptidic Chlamydia HtrA inhibitors

Agbowuro, AA; Hwang, J; Peel, E; Mazraani, R; Springwald, A; Marsh, JW; McCaughey, L; Gamble, AB; Huston, WM; Tyndall, JDA

doi:10.1016/j.bmc.2019.07.049

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Structure-activity analysis of peptidic Chlamydia HtrA inhibitors

MPS-Authors

There are no MPG-Authors in the publication available

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Agbowuro, A., Hwang, J., Peel, E., Mazraani, R., Springwald, A., Marsh, J., et al. (2019). Structure-activity analysis of peptidic Chlamydia HtrA inhibitors. Bioorganic & Medicinal Chemistry, 27(18), 4185-4199. doi:10.1016/j.bmc.2019.07.049.

Cite as: https://hdl.handle.net/21.11116/0000-000B-16BC-9

Abstract

Chlamydia trachomatis high temperature requirement A (CtHtrA) is a serine protease that performs proteolytic and chaperone functions in pathogenic Chlamydiae; and is seen as a prospective drug target. This study details the strategies employed in optimizing the irreversible CtHtrA inhibitor JO146 [Boc-Val-Pro-ValP(OPh)2] for potency and selectivity. A series of adaptations both at the warhead and specificity residues P1 and P3 yielded 23 analogues, which were tested in human neutrophil elastase (HNE) and CtHtrA enzyme assays as well as Chlamydia cell culture assays. Trypsin and chymotrypsin inhibition assays were also conducted to measure off-target selectivity. Replacing the phosphonate moiety with α-ketobenzothiazole produced a reversible analogue with considerable CtHtrA inhibition and cell culture activity. Tertiary leucine at P3 (8a) yielded approximately 33-fold increase in CtHtrA inhibitory activity, with an IC50 = 0.68 ± 0.02 µM against HNE, while valine at P1 retained the best anti-chlamydial activity. This study provides a pathway for obtaining clinically relevant inhibitors.